<DOC>
	<DOCNO>NCT02235324</DOCNO>
	<brief_summary>This phase II trial study long take colorectal cancer resistant standard treatment grow receive treatment ziv-aflibercept , well add fluorouracil leucovorin calcium ziv-aflibercept work treat patient stage IV colorectal cancer progress ziv-aflibercept alone . Ziv-aflibercept may stop growth colorectal cancer block formation tumor blood vessel . Fluorouracil leucovorin calcium drug use chemotherapy . Fluorouracil work stop growth tumor cell prevent cell grow divide . Leucovorin calcium help fluorouracil work well . Adding fluorouracil leucovorin calcium ziv-aflibercept may effective treatment patient progress ziv-aflibercept alone .</brief_summary>
	<brief_title>Ziv-Aflibercept Followed Ziv-Aflibercept , Fluorouracil , Leucovorin Calcium Treating Patients With Stage IV Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine progression‐free survival first phase study ( PFS1 ) patient metastatic colorectal cancer treat single agent ziv‐aflibercept progress leucovorin calcium , fluorouracil , oxaliplatin ( FOLFOX ) leucovorin calcium , fluorouracil , irinotecan hydrochloride ( FOLFIRI ) bevacizumab +/‐ cetuximab panitumumab . II . To determine progression‐free survival ( PFS2 ) patient metastatic colorectal cancer treat ziv‐aflibercept 5‐fluorouracil ( fluorouracil ) , progress ziv‐aflibercept alone . SECONDARY OBJECTIVES : I . Overall survival . II . Response rate . III . Incidence nature adverse event . IV . Growth modulation index ( ratio PFS2/PFS1 ) . TERTIARY OBJECTIVES : I . To determine relevant biomarkers distinguish patient progression free survival great 3 month single agent ziv‐aflibercept ( tumor vascular endothelial growth factor [ VEGF ] , vascular endothelial growth factor receptor [ VEGFR ] 1 2 , baseline plasma phosphatidylinositol glycan anchor biosynthesis , class F [ PlGF ] ) . II . Plasma level VEGF‐A , B , C , D , intercellular adhesion molecule 1 ( ICAM ) , chemokine ( C-X-C motif ) ligand 1 ( melanoma growth stimulate activity , alpha ) ( Gro alpha ) , hepatocyte growth factor ( HGF ) , stem cell growth factor beta ( SCGF beta ) prior treatment cycle therapy . III . Single nucleotide polymorphism ( SNPs ) VEGFA , VEGFR1 &amp; 2 &amp; 3 , interleukin ( IL ) 8 , angiopoietin-2 ( Ang2 ) , IL‐6 , ICAM , PlGF , neuropilin ( NRP ) 1 &amp; 2 , chemokine ( C-X-C motif ) receptor 2 ( CXCR2 ) others angiogenic pathway . IV . Tumor messenger ribonucleic acid ( mRNA ) expression level VEGF B , C , D , VEGFR 3 ; NRP 1 , 2 , VEGF isoforms biopsy specimen take trial initiation upon disease progression addition 5‐FU . V. Correlation biomarkers toxicity ziv‐aflibercept alone 5‐FU . OUTLINE : PHASE I : Patients receive ziv‐aflibercept intravenously ( IV ) 1 hour day 1 . Courses repeat every 14 day absence disease progression unacceptable toxicity . At time progression , patient proceed Phase II . PHASE II : Patients receive ziv‐aflibercept IV 1 hour , leucovorin calcium IV 1 minute , fluorouracil IV 46 hour day 1 . Courses repeat every 14 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Histologically confirm stage IV colorectal adenocarcinoma previously treat FOLFOX FOLFIRI bevacizumab , receipt cetuximab panitumumab require , show progression intolerant oxaliplatin irinotecan‐based regimen ; baseline tumor assessment must do within 28 day start treatment Patients must lesions easily biopsied Representative tumor tissue specimen ( paraffin block prefer ) Signed informed consent prior initiation study‐specific procedure treatment , include agreement two biopsy study Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Able comply protocol , include tissue blood sample Leukocytes &gt; = 3,000 per mm^3 Absolute neutrophil count &gt; = 1,000 per mm^3 Platelet count &gt; = 75,000 per mm^3 Hemoglobin &gt; = 9 g/dL ( may transfuse maintain exceed level ) Creatinine clearance accord Cockcroft Gault formula &gt; = 50 mL/min Urine proteinuria &lt; 2 + ; patient discover &gt; = 2 + proteinuria dipstick urinalysis baseline undergo 24‐hour urine collection must demonstrate &lt; 1 g protein 24 hour Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase alanine aminotransferase &lt; 2.5 x ULN International normalize ratio = &lt; 1.5 activated prothrombin time = &lt; 1.5 x ULN patient receive anti‐coagulation therapy The use full‐dose oral parenteral anticoagulant permit long international normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) within therapeutic limit ( accord medical standard enrol institution ) , patient stable dose anticoagulant least two week prior first study treatment Female patient pregnant breast‐feeding A female child‐bearing potential woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : Has undergone hysterectomy bilateral oophorectomy ; OR Has naturally postmenopausal least 12 consecutive month ( i.e . menses time precede 12 month ) Female patient childbearing potential agree use effective , non‐hormonal mean contraception ( intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly surgically sterile ) study period least 6 month follow last administration study drug Female patient intact uterus ( unless amenorrheic last 24 month ) must negative serum pregnancy test within 7 day prior randomization study Male patient must agree use effective contraception study period least 6 month follow last administration study drug , even surgically sterilize Any prior systemic treatment target antiangiogenic agent except bevacizumab ; receipt cetuximab panitumumab exclusion criterion Radiotherapy site reason within 14 day prior treatment Uncontrolled intercurrent illness include , limited Any follow within 6 month prior inclusion : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association ( NYHA ) class III IV congestive heart failure , stroke transient ischemic attack Any follow within 3 month prior inclusion : grade 34 gastrointestinal bleeding/hemorrhage ( unless due resect tumor ) , treatment resistant peptic ulcer disease , erosive esophagitis gastritis , infectious inflammatory bowel disease , diverticulitis , pulmonary embolism uncontrolled thromboembolic event History allergic reaction attribute compound similar chemical biologic composition agent use study History arterial thromboembolic event History abdominal fistula formation , gastrointestinal perforation , abdominal abscess within six month History evidence inherit bleed diathesis coagulopathy risk bleed Patients must pregnant nursing Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study drug Any hemorrhage bleeding event &gt; = CTCAE grade 3 within 4 week prior start study medication Non‐healing wound , ulcer , bone fracture Inadequately control hypertension ( systolic blood pressure [ SBP ] &gt; 150 mmHg , diastolic blood pressure [ DBP ] &gt; 100 mg Hg ) Known positivity human immunodeficiency virus ( HIV ) Malignancies colorectal adenocarcinoma within 5 year prior treatment , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent Clinically detectable ( physical exam ) third‐space fluid collection ( e.g . ascites pleural effusion ) control drainage procedure prior study entry Treatment investigational agent , participation another investigational drug trial within 28 day prior randomization Patients withdraw consent anytime study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>